BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...oral films containing apomorphine from Aquestive Therapeutics Inc. (NASDAQ:AQST). Kadmon’s GvHD therapy heading for FDA Kadmon Holdings Inc....
...of motor neuron 1 telomeric SMN2 - Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento...
BioCentury | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

...gained $15.96 to $203.44 Thursday. Also raising capital on the back of positive data was Kadmon Holdings Inc....
...after proposing the offering at a 5% discount to its close that day. On Monday, Kadmon...
...chronic graft-versus-host disease (see “Early Success in GvHD sets up NDA for Kadmon’s Lead” ). Kadmon’s...
BioCentury | Nov 12, 2019
Clinical News

Early success in GvHD sets up NDA for Kadmon’s lead

...primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon...
...NDA next year for KD025 following next half's primary analysis. On a conference call Monday, Kadmon Holdings Inc....
...Because the interim analysis covers all the trial's patients, the best ORR will not decrease. Kadmon...
BioCentury | Oct 25, 2019
Company News

Management tracks: Akouos, Kronos and Noveome

...McCracken as SVP of operations. He was VP of CMC at the Kadmon Pharmaceuticals LLC subsidiary of Kadmon Holdings Inc....
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

Kadmon Holdings Inc. (NYSE:KDMN) said Bart Schwartz is stepping down as chairman, citing Schwartz’s increasing responsibilities at his charitable commitments. The inflammatory and fibrotic disease company is seeking a successor. CytoDyn Inc. (OTCBB:CYDY) hired Nitya...
BioCentury | Jun 15, 2018
Financial News

Ahead of new trials, Kadmon raises $100M

...Kadmon's close of $3.35 on June 11, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...Drug designation in the U.S. to treat chronic GvHD. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Allison Johnson KD025, slx-2119 Kadmon Holdings Inc. Rho-associated...
BioCentury | Jun 15, 2018
Financial News

MeiraGTx trades flat after $75M IPO

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon Holdings Inc....
BioCentury | Jun 12, 2018
Financial News

Kadmon raises $100M ahead of new trials

...to Kadmon's close of $3.35 on Monday, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...2 (ROCK2). It has Orphan Drug designation in the U.S. to treat chronic GvHD. Allison Johnson KD025, slx-2119 Kadmon Holdings Inc. Rho-associated...
BioCentury | Jun 8, 2018
Financial News

MeiraGTx trades flat after $75M IPO

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon Holdings Inc....
...ophthalmologic pipeline via the acquisition of Athena Vision plc, a spinout from University College London. Paul Bonanos Kadmon Holdings Inc. MeiraGTx...
BioCentury | May 18, 2018
Financial News

MeiraGTx proposes $86.3M IPO

...Kadmon Holdings Inc. (NYSE:KDMN), which remains its largest shareholder with a 17.7% stake. MeiraGTx holds rights to Kadmon's...
...switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes was Kadmon's...
...officer. Since its establishment, MeiraGTx has raised more than $110 million in venture financing. After Kadmon...
Items per page:
1 - 10 of 85
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...oral films containing apomorphine from Aquestive Therapeutics Inc. (NASDAQ:AQST). Kadmon’s GvHD therapy heading for FDA Kadmon Holdings Inc....
...of motor neuron 1 telomeric SMN2 - Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento...
BioCentury | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

...gained $15.96 to $203.44 Thursday. Also raising capital on the back of positive data was Kadmon Holdings Inc....
...after proposing the offering at a 5% discount to its close that day. On Monday, Kadmon...
...chronic graft-versus-host disease (see “Early Success in GvHD sets up NDA for Kadmon’s Lead” ). Kadmon’s...
BioCentury | Nov 12, 2019
Clinical News

Early success in GvHD sets up NDA for Kadmon’s lead

...primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon...
...NDA next year for KD025 following next half's primary analysis. On a conference call Monday, Kadmon Holdings Inc....
...Because the interim analysis covers all the trial's patients, the best ORR will not decrease. Kadmon...
BioCentury | Oct 25, 2019
Company News

Management tracks: Akouos, Kronos and Noveome

...McCracken as SVP of operations. He was VP of CMC at the Kadmon Pharmaceuticals LLC subsidiary of Kadmon Holdings Inc....
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

Kadmon Holdings Inc. (NYSE:KDMN) said Bart Schwartz is stepping down as chairman, citing Schwartz’s increasing responsibilities at his charitable commitments. The inflammatory and fibrotic disease company is seeking a successor. CytoDyn Inc. (OTCBB:CYDY) hired Nitya...
BioCentury | Jun 15, 2018
Financial News

Ahead of new trials, Kadmon raises $100M

...Kadmon's close of $3.35 on June 11, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...Drug designation in the U.S. to treat chronic GvHD. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Allison Johnson KD025, slx-2119 Kadmon Holdings Inc. Rho-associated...
BioCentury | Jun 15, 2018
Financial News

MeiraGTx trades flat after $75M IPO

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon Holdings Inc....
BioCentury | Jun 12, 2018
Financial News

Kadmon raises $100M ahead of new trials

...to Kadmon's close of $3.35 on Monday, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...2 (ROCK2). It has Orphan Drug designation in the U.S. to treat chronic GvHD. Allison Johnson KD025, slx-2119 Kadmon Holdings Inc. Rho-associated...
BioCentury | Jun 8, 2018
Financial News

MeiraGTx trades flat after $75M IPO

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon Holdings Inc....
...ophthalmologic pipeline via the acquisition of Athena Vision plc, a spinout from University College London. Paul Bonanos Kadmon Holdings Inc. MeiraGTx...
BioCentury | May 18, 2018
Financial News

MeiraGTx proposes $86.3M IPO

...Kadmon Holdings Inc. (NYSE:KDMN), which remains its largest shareholder with a 17.7% stake. MeiraGTx holds rights to Kadmon's...
...switch on and off the expression of transgenes. MeiraGTx's President and CEO Alexandria Forbes was Kadmon's...
...officer. Since its establishment, MeiraGTx has raised more than $110 million in venture financing. After Kadmon...
Items per page:
1 - 10 of 85